Literature DB >> 18248809

Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3.

Laura Kotaniemi-Talonen1, Ahti Anttila, Nea Malila, Jussi Tarkkanen, Pekka Laurila, Matti Hakama, Pekka Nieminen.   

Abstract

AIM: To determine cross-sectional validity of primary human papillomavirus (HPV) screening in comparison to cytological screening.
METHODS: During 2003-2004, 61,149 women were individually randomised to screening with a test for oncogenic HPV DNA or to conventional cytological screening within the Finnish cervical screening programme.
RESULTS: For HPV screening, cross-sectional relative sensitivity for cervical intraepithelial neoplasia (CIN) or cancer was 1.58 (95 % confidence interval 1.19-2.09) in comparison to cytology. At the level of CIN 3 or cancer no increase in relative sensitivity was observed. Cross-sectional specificity estimates for the screening arms were comparable, but the specificity of screening with sole HPV DNA test was clearly inferior.
CONCLUSIONS: Primary HPV screening with cytology triage finds more CIN lesions compared to conventional screening but mild lesions are overrepresented. This is likely to result in overdiagnosis since most mild lesions are regressive.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248809     DOI: 10.1016/j.ejca.2007.12.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.

Authors:  Anne Szarewski; David Mesher; Louise Cadman; Janet Austin; Lesley Ashdown-Barr; Linda Ho; George Terry; Stuart Liddle; Martin Young; Mark Stoler; Julie McCarthy; Corrina Wright; Christine Bergeron; W P Soutter; Deirdre Lyons; Jack Cuzick
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

2.  High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions.

Authors:  Liverani Ca; Ciavattini A; Monti E; Puglia D; Mangano S; D I Giuseppe J; Zizzi A; Goteri G; Bolis G
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

Review 3.  Primary HPV screening for cervical cancer prevention: results from European trials.

Authors:  Elsebeth Lynge; Matejka Rebolj
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

4.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

5.  A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Authors:  Gina S Ogilvie; Dirk J van Niekerk; Mel Krajden; Ruth E Martin; Thomas G Ehlen; Kathy Ceballos; Stuart J Peacock; Laurie W Smith; Lisa Kan; Darrel A Cook; Wendy Mei; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  BMC Cancer       Date:  2010-03-24       Impact factor: 4.430

6.  Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening.

Authors:  M Rebolj; E Lynge
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 7.  Human papillomavirus testing for primary cervical cancer screening.

Authors:  Carolyn D Runowicz; Stephanie Garozzo
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

8.  Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.

Authors:  Gina S Ogilvie; Laurie W Smith; Dirk J van Niekerk; Fareeza Khurshed; Mel Krajden; Mona Saraiya; Vivek Goel; Barbara K Rimer; Sandra B Greene; Suzanne Hobbs; Andrew J Coldman; Eduardo L Franco
Journal:  Int J Cancer       Date:  2013-07-16       Impact factor: 7.396

9.  Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition.

Authors:  Jae Kwan Lee; Jin Hwa Hong; Sokbom Kang; Dae-Yeon Kim; Byoung-Gie Kim; Sung-Hoon Kim; Yong-Man Kim; Jae-Weon Kim; Jae-Hoon Kim; Tae-Jin Kim; Hyun Jung Kim; Hye Sun Kim; Hee-Sug Ryu; Jae Yun Song; Hyeong Sik Ahn; Chong Woo Yoo; Hye-Kyoung Yoon; Keun-Ho Lee; Ahwon Lee; Yonghee Lee; In Ho Lee; Jeong-Won Lee; Taek Sang Lee; Myong Cheol Lim; Suk-Joon Chang; Hyun Hoon Chung; Woong Ju; Hee Jae Joo; Soo-Young Hur; Sung-Ran Hong; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

10.  Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.

Authors:  Ahti Anttila; Laura Kotaniemi-Talonen; Maarit Leinonen; Matti Hakama; Pekka Laurila; Jussi Tarkkanen; Nea Malila; Pekka Nieminen
Journal:  BMJ       Date:  2010-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.